Neuropeptides in the Humane Intra- og Extracerebral Circulation.

Danish Headache Center

Status: Completed

Conditions: Healthy; Migraine

Treatments: Drug: sumatriptan

Study type: Interventional

Funder types: Other

Identifiers

NCT00399633

Neuropeptide2007

Details and patient eligibility

About

The study aim at examining whether Sumatriptan changes the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.

Full description

The study is meant to give a better understanding of the basic mechanisms behind migraine, and a better understanding of the effects of sumatriptan on the trigemino vascular system.

The endpoints are changes in the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.

Enrollment: 16 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy volunteers
• 18-50 years,
• 50-100 kg.
• Fertile women must use birth control.

Exclusion criteria

• All primary types of headache
• Daily intake of medicine except birth control
• Pregnancy
• Hypertension
• Hypotension
• other chronic disease